Neomycin (topical)

Neomycin (topical)

Error creating thumbnail: File missing
Clinical data
ATC code	A01AB08 (WHO) A07AA01 (WHO), B05CA09 (WHO), D06AX04 (WHO), J01GB05 (WHO), R02AB01 (WHO), S01AA03 (WHO), S02AA07 (WHO), S03AA01 (WHO)
Pharmacokinetic data
Elimination half-life	2 to 3 hours
Identifiers
CAS Number	1404-04-2
PubChem CID	8378
DrugBank	APRD00013
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H46N6O13
Molar mass	614.644 g/mol

WikiDoc Resources for Neomycin (topical)
Articles
Most recent articles on Neomycin (topical) Most cited articles on Neomycin (topical) Review articles on Neomycin (topical) Articles on Neomycin (topical) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Neomycin (topical) Images of Neomycin (topical) Photos of Neomycin (topical) Podcasts & MP3s on Neomycin (topical) Videos on Neomycin (topical)
Evidence Based Medicine
Cochrane Collaboration on Neomycin (topical) Bandolier on Neomycin (topical) TRIP on Neomycin (topical)
Clinical Trials
Ongoing Trials on Neomycin (topical) at Clinical Trials.gov Trial results on Neomycin (topical) Clinical Trials on Neomycin (topical) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Neomycin (topical) NICE Guidance on Neomycin (topical) NHS PRODIGY Guidance FDA on Neomycin (topical) CDC on Neomycin (topical)
Books
Books on Neomycin (topical)
News
Neomycin (topical) in the news Be alerted to news on Neomycin (topical) News trends on Neomycin (topical)
Commentary
Blogs on Neomycin (topical)
Definitions
Definitions of Neomycin (topical)
Patient Resources / Community
Patient resources on Neomycin (topical) Discussion groups on Neomycin (topical) Patient Handouts on Neomycin (topical) Directions to Hospitals Treating Neomycin (topical) Risk calculators and risk factors for Neomycin (topical)
Healthcare Provider Resources
Symptoms of Neomycin (topical) Causes & Risk Factors for Neomycin (topical) Diagnostic studies for Neomycin (topical) Treatment of Neomycin (topical)
Continuing Medical Education (CME)
CME Programs on Neomycin (topical)
International
Neomycin (topical) en Espanol Neomycin (topical) en Francais
Business
Neomycin (topical) in the Marketplace Patents on Neomycin (topical)
Experimental / Informatics
List of terms related to Neomycin (topical)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Neomycin is an aminoglycoside antibiotic that is found in many topical medications such as creams, ointments and eyedrops.

Uses

Neomycin is overwhelmingly used as a topical preparation. It can also be given orally, where it is usually combined with other antibiotics. Neomycin is not absorbed from the gastrointestinal tract, and has been used as a preventative measure for hepatic encephalopathy and hypercholesterolemia. By killing bacteria in the intestinal tract, it keeps ammonia levels low and prevents hepatic encephalopathy, especially prior to GI surgery. It has also been used to treat small intestinal bacterial overgrowth. It is not given intravenously, as neomycin is extremely nephrotoxic (causes kidney damage), especially compared to other aminoglycosides. The exception to this, is when it is included in some vaccines as a preservative, but in very small quantities -typically 0.025 mg per dose[3].

Spectrum

Similar to other aminoglycosides, neomycin has excellent activity against Gram negative bacteria, and has partial activity against Gram positive bacteria. It is relatively toxic to humans, and some people have allergic reactions to it. See: Hypersensitivity.

Neomycin is used in the laboratory on agar plates to grow mutant forms of bacteria that carry genes for resistance to neomycin. The resistant genes to neomycin are found within the plasmid of the bacteria; which may or may not be incorporated into the bacteria's circular chromosome.

History

Neomycin was discovered in 1949 by the microbiologist Selman Waksman and his student Hubert Lechevalier. It is produced naturally by the bacterium Streptomyces fradiae.

References

Template:AminoglycosideAntiBiotics Template:Throat preparations Template:Otologicals
Template:SIB